Bank of New York Mellon Corp Sells 21,026 Shares of Revvity Inc. $RVTY

Bank of New York Mellon Corp trimmed its position in shares of Revvity Inc. (NYSE:RVTY) by 3.2% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 637,406 shares of the company’s stock after selling 21,026 shares during the quarter. Bank of New York Mellon Corp’s holdings in Revvity were worth $55,843,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Ascentis Independent Advisors bought a new position in shares of Revvity during the 1st quarter worth approximately $29,000. CYBER HORNET ETFs LLC acquired a new stake in Revvity in the second quarter valued at approximately $32,000. Cromwell Holdings LLC boosted its stake in Revvity by 141.4% in the fourth quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock valued at $33,000 after acquiring an additional 198 shares in the last quarter. MUFG Securities EMEA plc purchased a new position in Revvity in the second quarter worth $34,000. Finally, Headlands Technologies LLC acquired a new position in shares of Revvity during the second quarter worth $49,000. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Analyst Upgrades and Downgrades

RVTY has been the subject of a number of recent analyst reports. Wolfe Research began coverage on Revvity in a research report on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Sanford C. Bernstein began coverage on Revvity in a research note on Friday, June 26th. They issued a “market perform” rating and a $115.00 price target for the company. The Goldman Sachs Group lowered their price target on Revvity from $110.00 to $95.00 and set a “neutral” rating for the company in a report on Tuesday, April 14th. Evercore reaffirmed an “outperform” rating and issued a $125.00 price objective on shares of Revvity in a research report on Monday, July 6th. Finally, Robert W. Baird set a $117.00 target price on shares of Revvity in a research note on Wednesday, May 6th. Four research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Revvity presently has an average rating of “Hold” and an average target price of $108.92.

Revvity Stock Performance

NYSE RVTY opened at $113.21 on Friday. The firm has a market capitalization of $12.63 billion, a P/E ratio of 54.17, a PEG ratio of 2.18 and a beta of 1.09. The stock has a 50-day simple moving average of $104.57 and a two-hundred day simple moving average of $99.53. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.41 and a current ratio of 1.72. Revvity Inc. has a fifty-two week low of $81.22 and a fifty-two week high of $118.30.

Revvity (NYSE:RVTY) last issued its earnings results on Tuesday, May 5th. The company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. Revvity had a return on equity of 8.00% and a net margin of 8.26%.The firm had revenue of $711.12 million for the quarter, compared to the consensus estimate of $704.07 million. During the same quarter in the prior year, the business earned $1.01 earnings per share. The company’s revenue was up 7.0% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. On average, equities analysts forecast that Revvity Inc. will post 5.25 earnings per share for the current year.

Revvity Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, August 7th. Investors of record on Friday, July 17th will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.2%. The ex-dividend date is Friday, July 17th. Revvity’s payout ratio is currently 13.40%.

Revvity Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.